Literature DB >> 34255165

[80 milestones in rheumatology from 80 years-IV. 2000-2020].

T Dörner1,2, G Schett3,4.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34255165     DOI： 10.1007/s00393-021-01038-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  56 in total

1.  Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.

Authors:  Gerd R Burmester; Frank Buttgereit; Corrado Bernasconi; Jose M Álvaro-Gracia; Nidia Castro; Maxime Dougados; Cem Gabay; Jacob M van Laar; Jan Michael Nebesky; Attila Pethoe-Schramm; Carlo Salvarani; Marc Y Donath; Markus R John
Journal:  Lancet       Date:  2020-07-25       Impact factor: 79.321

2.  Rituximab for IgG4-related disease: a prospective, open-label trial.

Authors:  Mollie N Carruthers; Mark D Topazian; Arezou Khosroshahi; Thomas E Witzig; Zachary S Wallace; Philip A Hart; Vikram Deshpande; Thomas C Smyrk; Suresh Chari; John H Stone
Journal:  Ann Rheum Dis       Date:  2015-02-09       Impact factor: 19.103

3.  Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.

Authors:  Laura C Coates; Anna R Moverley; Lucy McParland; Sarah Brown; Nuria Navarro-Coy; John L O'Dwyer; David M Meads; Paul Emery; Philip G Conaghan; Philip S Helliwell
Journal:  Lancet       Date:  2015-10-01       Impact factor: 79.321

4.  Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.

Authors:  Frank Buttgereit; Gisela Doering; Achim Schaeffler; Stephan Witte; Stanislaw Sierakowski; Erika Gromnica-Ihle; Slawomir Jeka; Klaus Krueger; Jacek Szechinski; Rieke Alten
Journal:  Lancet       Date:  2008-01-19       Impact factor: 79.321

5.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Authors:  Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

6.  A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.

Authors:  Pirow J Bekker; Donna L Holloway; Amy S Rasmussen; Robyn Murphy; Steven W Martin; Philip T Leese; Gregory B Holmes; Colin R Dunstan; Alex M DePaoli
Journal:  J Bone Miner Res       Date:  2004-03-01       Impact factor: 6.741

7.  Locally renewing resident synovial macrophages provide a protective barrier for the joint.

Authors:  Stephan Culemann; Anika Grüneboom; José Ángel Nicolás-Ávila; Daniela Weidner; Katrin Franziska Lämmle; Tobias Rothe; Juan A Quintana; Philipp Kirchner; Branislav Krljanac; Martin Eberhardt; Fulvia Ferrazzi; Elke Kretzschmar; Martin Schicht; Kim Fischer; Kolja Gelse; Maria Faas; René Pfeifle; Jochen A Ackermann; Milena Pachowsky; Nina Renner; David Simon; Reiner F Haseloff; Arif B Ekici; Tobias Bäuerle; Ingolf E Blasig; Julio Vera; David Voehringer; Arnd Kleyer; Friedrich Paulsen; Georg Schett; Andrés Hidalgo; Gerhard Krönke
Journal:  Nature       Date:  2019-08-07       Impact factor: 49.962

8.  The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.

Authors:  Tobias Alexander; Ramona Sarfert; Jens Klotsche; Anja A Kühl; Andrea Rubbert-Roth; Hannes-Martin Lorenz; Jürgen Rech; Bimba F Hoyer; Qingyu Cheng; Aderajew Waka; Adriano Taddeo; Michael Wiesener; Georg Schett; Gerd-Rüdiger Burmester; Andreas Radbruch; Falk Hiepe; Reinhard E Voll
Journal:  Ann Rheum Dis       Date:  2015-02-20       Impact factor: 19.103

9.  Distinct fibroblast subsets drive inflammation and damage in arthritis.

Authors:  Adam P Croft; Joana Campos; Kathrin Jansen; Jason D Turner; Jennifer Marshall; Moustafa Attar; Loriane Savary; Corinna Wehmeyer; Amy J Naylor; Samuel Kemble; Jenefa Begum; Kerstin Dürholz; Harris Perlman; Francesca Barone; Helen M McGettrick; Douglas T Fearon; Kevin Wei; Soumya Raychaudhuri; Ilya Korsunsky; Michael B Brenner; Mark Coles; Stephen N Sansom; Andrew Filer; Christopher D Buckley
Journal:  Nature       Date:  2019-05-29       Impact factor: 49.962

10.  Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.

Authors:  Dominique Baeten; Xenofon Baraliakos; Jürgen Braun; Joachim Sieper; Paul Emery; Désirée van der Heijde; Iain McInnes; Jacob M van Laar; Robert Landewé; Paul Wordsworth; Jürgen Wollenhaupt; Herbert Kellner; Jacqueline Paramarta; Jiawei Wei; Arndt Brachat; Stephan Bek; Didier Laurent; Yali Li; Ying A Wang; Arthur P Bertolino; Sandro Gsteiger; Andrew M Wright; Wolfgang Hueber
Journal:  Lancet       Date:  2013-09-13       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.